Gossamer Bio: Seralutinib’s Phase 3 PROSERA Trial as a 2026 Value-Defining Catalyst Supporting Buy Rating and $10 Target

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Gossamer Bio, retaining the price target of $10.00.

Patrick Trucchio has given his Buy rating due to a combination of factors that, in his view, position Gossamer Bio for a value-defining catalyst in 2026. He highlights that the Phase 3 PROSERA trial of seralutinib in pulmonary arterial hypertension appears well designed, with patient selection and endpoints that increase the likelihood of achieving a clinically meaningful improvement in six-minute walk distance. He also emphasizes that management’s guidance around what would constitute a successful top-line result, combined with the company’s clear focus on long-term functional benefit rather than a single 24-week snapshot, supports a favorable risk‑reward profile ahead of the readout.
In addition, Trucchio underscores that seralutinib is not simply another vasodilator but was engineered from the outset as a potential disease‑modifying therapy targeting vascular remodeling, inflammation, and fibrosis via PDGFR, CSF1R, and c‑KIT pathways. He points to more compelling efficacy signals in the appropriate Phase 2 TORREY patient subgroup, including improvements in exercise capacity, pulmonary vascular resistance, and NT‑proBNP, which informed the Phase 3 design. He views the sustained clinical gains observed out to 72 weeks in the open‑label extension as a particularly underappreciated strength, reinforcing the drug’s durability and mechanistic differentiation, and together these elements underpin his decision to reiterate a Buy rating and a $10 price target on GOSS.

In another report released on January 12, Piper Sandler also maintained a Buy rating on the stock with a $15.00 price target.